Hutch News

Hutch News

Stories tagged 'clinical trials'

What's new in prostate cancer: 5 takeaways

‘Many reasons for optimism’ says expert at annual community symposium

May 1, 2018 | by Susan Keown / Fred Hutch News Service

What's new in prostate cancer in 2018? The latest in prostate cancer treatment, screening, survivorship and more.

View story >


Early phase clinical trial shows promise for advanced head and neck cancer

Nine out of 10 patients treated with the experimental therapy saw their tumors shrink

April 13, 2018 | By Rachel Tompa / Fred Hutch News Service

When you look at Carla Stone, you might not guess that she was diagnosed with stage 4 head and neck cancer just two years ago. Stone participated in a clinical trial that shrank her advanced tumor down to nothing, allowing her to undergo a minimally invasive surgery.

View story >


With approval of new CMV drug for transplant patients, a legacy continues

Tissue samples from a clinical trial conducted decades ago yield new insights and treatments

April 12, 2018 | By Mary Engel / Fred Hutch News Service

Tissue samples from a landmark clinical trial conducted decades ago by the late Dr. Joel Meyers yield new insights and treatments

View story >


Meet Global Oncology's deputy program head

Key early experiences shaped Dr. Thomas Uldrick's path toward HIV-associated cancers, global health

Feb. 22, 2018 | By Mary Engel / Fred Hutch News Service

Dr. Thomas Uldrick brings expertise in HIV-related cancers and experience in — and a passion for — developing clinical trials to his new position at Fred Hutch Global Oncology.

View story >


How new drugs become available to more patients

Filling in the unknowns on the balance between risk and benefit

Feb. 9, 2018 | by Susan Keown / Fred Hutch News Service

Often, new drugs are only approved to treat patients with advanced disease. But that can change as evidence accrues on the drugs’ risks and benefits.

View story >


New insights into CAR T-cell therapy's potential side effects

Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer

Dec. 11, 2017 | By Fred Hutch staff

Detailed studies of two potential side effects of an emerging cancer immunotherapy could eventually help make this strategy, CAR T-cell therapy, safer for patients. The studies examined cytokine release syndrome and neurologic toxicities.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.